BEAM - Beam Therapeutics GAAP EPS of -$1.22 beats by $0.03 revenue of $17.19M misses by $6.7M
2023-11-08 06:46:46 ET
More on Beam Therapeutics
- Beam: Opportunity Based On SCD Data Readout In 2024
- Beam Therapeutics: Rich In Cash, Poor In Punctuality (Rating Downgrade)
- Eli Lilly marks gene editing foray in deal with Beam
- Editas upgraded at Citi ahead of FDA AdCom on gene editing therapy
- Seeking Alpha’s Quant Rating on Beam Therapeutics
For further details see:
Beam Therapeutics GAAP EPS of -$1.22 beats by $0.03, revenue of $17.19M misses by $6.7M